Shopping Cart
Remove All
Your shopping cart is currently empty
TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $106 | In Stock | In Stock | |
| 5 mg | $268 | In Stock | In Stock | |
| 10 mg | $428 | In Stock | In Stock | |
| 25 mg | $785 | In Stock | In Stock | |
| 50 mg | $1,120 | In Stock | In Stock | |
| 100 mg | $1,480 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $295 | In Stock | In Stock |
| Description | TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy. |
| Targets&IC50 | Cav 3.1 (a1G):89 nM, Cav 3.2 (a1H):92 nM |
| In vivo | TTA-A2 (oral gavage; 10 mg/kg; once daily; 5 days) shows selective effect on recurrent thalamocortical network activity, it suppresses active wake and promotes slow-wave sleep in wild-type mice but not in mice lacking both Cav3.1 and Cav3.3[1].TTA-A2 (oral gavage;?3 mg/kg;?single dose) produces significant changes in sleep architecture in rats.?A reduction in active wake soon after dosing with a concurrent increase in delta sleep and decrease in REM sleep.?Additionally, these effects persists for up to 4 h post-dose in rats[2]. |
| Molecular Weight | 378.39 |
| Formula | C20H21F3N2O2 |
| Cas No. | 953778-63-7 |
| Smiles | C[C@@H](NC(=O)Cc1ccc(cc1)C1CC1)c1ccc(OCC(F)(F)F)cn1 |
| Relative Density. | 1.258 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (72.68 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2 mg/mL (5.29 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.